title: Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
abstract: OBJECTIVE
  . Adjuvant therapies have prolonged survival of non-metastatic breast cancer (NMBC) patients, but they also decrease bone mineral density (BMD). We have analyzed the effects of chemotherapy, hormone therapy with tamoxifen or both, on BMD of women with NMBC.
  
  
  METHODS
  We prospectively included 168 women with NMBC (stage I-III) referred to the Medical Oncology Service of University Hospital of Canary Islands between 1997 and 2001 (55 +/- 12 years; 37% premenopausal; 43 +/- 13 months of follow-up). We measured lumbar and hip BMD (g/cm2) at diagnosis, after chemotherapy and after 12 months of tamoxifen. If a low BMD was detected, women were treated with bisphosphonates.
  
  
  RESULTS
  BMD after chemotherapy (n = 83) significantly decreased at lumbar (1.014 +/- 0; 0.995 +/- 0, p = 0.0001), trochanter (0.701 +/- 0; 0.690 +/- 0, p = 0.001), intertrochanter (1.095 +/- 0; 1.078 +/- 0, p = 0.0001) and total hip (0.924 +/- 0; 0.915 +/- 0, p = 0.046) areas. Although 60% of the premenopausal women suffered amenorrhea after chemotherapy, there were not significant differences in BMD between them and women who retained menses. BMD of women who received 12 months of tamoxifen after chemotherapy increased--total hip (0.907 +/- 0; 0.922 +/- 0, p = 0.005) and intertrochanter (1.071 +/- 0; 1.091 +/- 0, p = 0.003)--or remained stable--lumbar, femoral neck, trochanter, and Ward's triangle (n = 39). When tamoxifen was the only adjuvant treatment, BMD after 12 months (n = 22) increased in trochanter area (0.644 +/- 0; 0.663 +/- 0, p = 0.011), and remained stable in all other sites. 50 (30%) patients were treated with bisphosphonates because of osteopenia.
  
  
  CONCLUSIONS
  Women with NMBC are affected by early bone loss after adjuvant chemotherapy. This bone loss is attenuated by one year of tamoxifen treatment.
authors.affiliation: Internal Medicine Service, University Hospital of Canary Islands (HUC) and La Laguna University, Spain.
authors.forename: Luz-Milva
authors.initials: LM
authors.lastname: Rodríguez-Rodríguez
authors.forename: Eva-María
authors.initials: EM
authors.lastname: Rodríguez-Rodríguez
authors.forename: Juana-María
authors.initials: JM
authors.lastname: Oramas-Rodríguez
authors.forename: Francisco
authors.initials: F
authors.lastname: Santolaria-Fernandez
authors.forename: Marta
authors.initials: M
authors.lastname: Llanos
authors.forename: Josefina
authors.initials: J
authors.lastname: Cruz
authors.forename: Antonio
authors.initials: A
authors.lastname: Martínez
authors.forename: Emilio
authors.initials: E
authors.lastname: González-Reimers
authors.forename: Angeles
authors.initials: A
authors.lastname: Gómez
authors.forename: Norberto
authors.initials: N
authors.lastname: Batista
mesh_terms: D000568:Amenorrhea / Q000139:chemically induced; D015519:Bone Density / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011446:Prospective Studies; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage* / Q000009:adverse effects; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen